Company Overview and News

94
Why I Am Acquiring More AT&T

5h seekingalpha
Editor's note: Seeking Alpha is proud to welcome AllStarTrader as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
T TMUS CMCSA TWX NFLX TWC DIS

6
TMUS / T-Mobile US, Inc. 425 (Prospectus)

6h sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Excha
TMUS

6
TMUS / T-Mobile US, Inc. 425 (Prospectus)

6h sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Excha
TMUS

8
TMUS / T-Mobile US, Inc. TMUS FORM S-8

2018-06-18 sec.gov
Document As filed with the Securities and Exchange Commission on June 18, 2018
TMUS

8
TMUS / T-Mobile US, Inc. TMUS FORM 8-K (Current Report)

2018-06-18 sec.gov
Document UNITED STATES
TMUS

9
Time For T-Mobile To Find A Different Dance Partner

2018-06-18 seekingalpha
T-Mobile and Sprint's merger should have a positive effect, too bad shareholders likely won't be included.
S TMUS

129
3 REITs to Buy in Times of Uncertainty

2018-06-18 investorplace
The real estate investment trust (REIT) industry usually suffers during uncertain times. If investors decide not to put capital into businesses, demand for office, retail, industrial, and often, apartment real estate tends to decline. Hence, finding REITs to buy can often become difficult during these periods. However, not all sectors see declines. Downturns often force unemployed workers to move in with family and friends.
PSA.PRA PSA.PRB AMT.PRB AMT.PRA PSA.A EXR VZA AMT PSAXZ PSA.PRG CCI PSA.PRE PSA.PRF PSA.PRC PSA.PRD VTR TMUSP TMUS PSA.PRY PSA.PRZ PSA.PRW PSA.PRX PSA.PRU PSA.PRV PSA PSA.PRS PSA.PRT T VZ SBAC

10
Uniti Means Opportunity

2018-06-18 seekingalpha
Today, I want to take a closer look at UNIT to determine the overall reliability of the dividend and the potential for adding new shares.
S UNIT TMUS LMRK HASI

41
Technically Speaking For The Week Of June 11-15

2018-06-17 seekingalpha
The U.S. trade situation continues to grow murkier. The G-7 meeting was an absolute disaster, ending with Trump picking a fight with Canada of all people (one of my favorite Facebook memes about this said "picking a fight with Canada is like kicking a Golden Retriever). Later in the week, we learned that Senate Republicans were unwilling to aid Bob Corker in supporting a measure that would limit the President's ability to levy tariffs against trading partners.
S T GOOGL TMUS TWX GOOG TWC

53
5 Stocks Rated Buy Under $10 With Massive Upside Potential

2018-06-16 247wallst
While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the amount of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the low to mid hundreds and all the way up to over $1,000 per share. At those steep prices, it’s pretty hard to get any decent share count leverage.
SPN DB S TMUSP TMUS WIREX AKS KOS

208
Look for Prospective Suitors to Call On Lions Gate Entertainment Corp.

2018-06-15 investorplace
Lions Gate Entertainment Corp. (USA) (NYSE:LGF.A,)(NYSE:LGF.B) is seeing a move upward on the approved merger of AT&T Inc. (NYSE:T) and Time Warner Inc (NYSE:TWX). With takeover approval, Lions Gate stock has gained interest on the theory that it too will become a takeover target. Media providers have targeted content companies to boost earnings amid declining profitability in their core industries.
FOX TMUSP LGF TMUS CCV CMCSA TWX NFLX CCZ TWC VZA S AMZN T CCV.CL VZ LGF.A LGF.B FOXA CMCSK DIS

34
Deals of the day-Mergers and acquisitions

2018-06-15 reuters
June 15 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:
TMUSP EDRVY TMUS SDRPQ LYB TWX TWC SD SDOCQ S EDPR LALWF EDRVF QCOM SDRXP SDRXQ

11
Sprint, T-Mobile plan to file deal application to FCC on Monday - Channel NewsAsia

2018-06-15 channelnewsasia
Wireless companies Sprint Corp and T-Mobile US Inc have informed the Federal Communications Commission that they will formally file an application asking for approval to merge on Monday, according to a document seen by Reuters.
S TMUSP TMUS

11
Sprint, T-Mobile plan to file deal application to FCC on Monday

2018-06-15 reuters
WASHINGTON (Reuters) - Wireless companies Sprint Corp and T-Mobile US Inc have informed the Federal Communications Commission that they will formally file an application asking for approval to merge on Monday, according to a document seen by Reuters.
S TMUSP TMUS

8
TMUS / T-Mobile US, Inc. TMUS FORM 8-K (Current Report)

2018-06-14 sec.gov
Document UNITED STATES
TMUS

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 872590104